Modernization of RSDL RFI_Final.pdf

W911SR-24-R-RSDL

REQUEST FOR INFORMATION

MODERNIZATION OF REACTIVE SKIN DECONTAMINATION LOTION (RSDL), A U.S.

FOOD AND DRUG ADMINISTRATION (FDA) APPROVED PRODUCT

Objective:

This is a Request for Information (RFI) for planning purposes only. It is not to be construed as a commitment by the government nor will the government pay for the information requested. No solicitation document exists or is guaranteed to be issued as a result of this RFI. The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) is seeking information on the available capabilities and willingness of private entities (academic, non-profit, and commercial) to collaborate with the government in the areas listed below.

Background:

The JPM CBRN Medical is interested in meeting the operational need for supporting fielded medical products. As such, the Department of Defense (DOD) has a need for modernizing fielded products. T h e JPEO-CBRND is responsible for the development, procurement, fielding, and sustainment of medical treatment and prophylactic capabilities against chemical, biological, radiological, and nuclear threats.

Requirements:

The government is seeking white papers outlining approaches for improving, modernizing or replacing RSDL®. The purpose of this RFI is to solicit information on the availability of companies capable of meeting the performance objectives. The modernized product will be an updated version of RSDL® that is at least as effective as the current RSDL®, with improvements so that it can be stored without the need of controlled storage conditions and/or has a shelf-life greater than five (5) years.

Performance Objectives:

a. Equal or higher efficacy as the current RSDL® in removing and decontaminating residual chemical agent on the skin, demonstrated by in vivo protective ratios against exposures to chemical threats

b. A product that can be stored without the use of controlled temperature and humidity

c. Shelf life greater than five (5) years.

d. A product able to be reshelved after distribution, if not used.

e. A product available in a personnel spot decontamination form, and also in an approved form to support bulk use in the event of a mass casualty scenario.

The respondents shall provide the following in reply to this RFI, not to exceed five (5) pages in total:

1. Company Description (one (1) page maximum).

Provide a brief description of the company’s history and industry/government partnerships.

Describe any Intellectual Property (IP) ownership complications or inherited IP

Identify relevant US patents and indicate whether they are pending or granted

2. Past Performance (one (1) page maximum).

Respondents should provide relevant past performance and experience outlining previous work with the US Government and/or industry and emphasizing experience in manufacturing products similar to RSDL®.

3. Modernization Plan (three (3) page maximum).

• Describe and discuss approaches to address the requirements in the Performance Objectives section; innovative approaches that do not precisely match the above Performance Objectives can also be included.

• Provide a plan that outlines a schedule necessary to meet the overarching program goals.

• Provide a non-binding Rough Order of Magnitude cost.

• Provide a notional intended use statement for the product and a description of the approach to bring it to market in the US.

Administration:

The government will retain comments and information received in response to this RFI. Proprietary information should be identified as Company Proprietary. Do not use government security classification markings. All written responses must be received by COB on 31 May 2024. Responses should be ONLY sent by e-mail to: usarmy.detrick.dod-jpeo-cbrnd.mbx.baa@army.mil, with the subject line of “Responding Organization” and “RFI Title”. Material that is advertisement only in nature is not desired.

If a solicitation is subsequently released based on the responses to this RFI, the first choice for an acquisition vehicle, if appropriate, will be an Other Transaction Authority (OTA) agreement issued under the Medical CBRN Defense Consortium (MCDC) or the Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Broad Agency Announcement (BAA) 22-01. Respondents interested in the MCDC can obtain information at www.medcbrn.org. Respondents may also inquire about the Medical Countermeasures BAA in SAM.gov, keywords CBRND-22-01. For questions related to this RFI, please send an e-mail to: usarmy.detrick.dod-jpeo-cbrnd.mbx.baa@army.mil.

mailto:%20usarmy.detrick.dod-jpeo-cbrnd.mbx.baa@army.mil, http://www.medcbrn.org./ mailto:usarmy.detrick.dod-jpeo-cbrnd.mbx.baa@army.mil.